View the mentioned paper here:

Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2839518

Access the mentioned course here:

Understanding Autism Spectrum Disorder: A Comprehensive Guide to Clinical Assessment & Diagnosis
https://psychscene.co/4zXOHNW

In this video, Dr Sanil Rege examines a 2025 randomised controlled trial of memantine for social impairment in young people with Autism Spectrum Disorder (ASD).

He explores whether memantine can improve social functioning and outlines how glutamatergic dysregulation, NMDA receptor modulation, and elevated anterior cingulate glutamate may help identify a biologically responsive subtype. He also considers how this may move the field beyond viewing autism as a single, uniform condition.

This session provides clinicians with a neurobiological framework for understanding autism through biomarkers, circuit dysfunction, and emerging precision psychiatry principles.

Chapters:
- Memantine for Social Impairment in Autism
- Why Autism May Not Be One Uniform Condition
- Trial Design and Participant Profile
- pGACC Glutamate as a Biomarker
- Response Rates and Subgroup Findings
- NMDA Receptors and Glutamatergic Mechanisms
- Memantine Versus Ketamine
- From Autism Spectrum to Neurobiological Subtypes

#Autism #Memantine #Psychiatry

Access mentioned course here:

Advanced Psychiatric Formulation and Strategic Management Masterclass

https://psychscene.co/3Rn0Sm3

Here is the link to the paper mentioned:
Towards a Consensus Roadmap for a New Diagnostic Framework for Mental Disorders
https://www.sciencedirect.com/science/article/pii/S0924977X24007168

In this episode, Dr Sanil Rege examines a 2025 ECNP consensus roadmap calling for psychiatry to move beyond descriptive diagnosis towards biology-informed, transdiagnostic, and mechanism-based models.

He explores how circuit biomarkers, inflammation, genomic overlap, digital phenotyping, and machine learning may refine patient stratification, treatment selection, and relapse prediction across traditional diagnostic boundaries.

This video provides clinicians with a neurobiological framework for shifting from label-based treatment to mechanism-informed formulation in psychiatric practice.

Chapters:
- A Roadmap for Mechanism-Based Psychiatry

- Why Labels Alone are No Longer Enough

- Shared Vulnerabilities Across Diagnostic Boundaries

- Neurocircuit Profiles and Treatment Response

- Inflammation and Targeted Intervention

- Data-Driven Subtypes and Machine Learning

- Biomarker-Enriched Trials and Future Drug Development

- Clinical Pearls for Mechanism-Informed Formulation

#Psychiatry #DSM5 #ICD11

Access the mentioned paper here:

Trying to Unravel Why Alzheimer Disease Is More Common in Women

By Rita Rubin, MA

https://jamanetwork.com/journals/jama/article-abstract/2839498#

Access mentioned courses here:

Women’s Mental Health Course:

https://psychscene.co/41RwJx2

Alzheimer’s Disease Course:

https://psychscene.co/4vNaeqH

In this episode, Dr Sanil Rege examines why Alzheimer’s disease is more common in women and what this means for clinical assessment, prevention, and treatment.

The discussion reviews a 2025 JAMA medical news feature (https://jamanetwork.com/journals/jama/article-abstract/2839498#) on sex differences in Alzheimer’s disease and outlines a life-course model showing how sex-related vulnerability may shape disease onset, progression, and clinical expression.

This video provides clinicians with a sex-informed clinical framework for assessing Alzheimer’s risk in women through the lens of hormonal transitions, cognitive reserve, and later-life neurodegenerative expression.

Chapters:

00:21 Alzheimer’s Disease in Women

02:59 Beyond Longevity

03:40 Survival Differences After Dementia Diagnosis

04:34 Tau Pathology and Steeper Later Decline

06:00 Menopause and Hormonal Vulnerability

08:11 Modifiable Midlife Risk Factors in Women

13:18 A Sex-Informed Life-Course Formulation1

#Alzheimer's #Psychiatry #Dementia